secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-09-24T12:12:10+00:00
Accession:  0001100682-26-000142
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River unveils 'Pathway to Purpose' strategy; reaffirms 2026 guidance at upper end
--------------------------------------------------------------------------------

- Announces 'Pathway to Purpose' strategy focused on modernization, scientific portfolio, and client-centric approach.
- Expects over $300M cumulative savings from Create the Future program (2027-2030) via automation and AI digital tools.
- Reaffirms 2026 guidance: organic revenue growth at upper end of 0%–1%; non-GAAP EPS at upper end of $11.15–$11.45.
- Introduces 2030 targets: 5%–7% organic revenue CAGR, ~24% non-GAAP operating margin, low-double-digit EPS CAGR.
- Bioanalysis revenue targeted at ~$450M by 2030; Apollo platform now serves 18,000 client users.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/0001100682-26-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000142/crl-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001100682-26-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer